SMA is the second most prevalent genetic cause of infant death in the UK, after cystic fibrosis. Studies show that between 1:50 and 1:34 of the population are carriers of the disease, and that it affects in the region of 1:10,000 children born in the UK. In the USA, 1:40 are carriers and 1:6,000 children are affected by the disease.
SMA is a neuromuscular condition causing weakness of the muscles. The gene for SMA is passed from parents to their children, but SMA can only affect a child if both parents carry a defective gene. Genes come in pairs, one from each parent. If a person has one normal and one affected gene they do not show the symptoms of SMA but are carriers. If both genes are affected they will have SMA.
Researchers at the Peninsula Medical School in Exeter, UK, have carried out studies into one of the two survival motor neuron (SMN) genes that set suffers from SMA apart from the rest of the population. In 98% of SMA sufferers, the SMN protein is only produced from one of these genes. The resulting fall in SMN protein levels is what causes SMA to develop.
The remaining two per cent of SMA sufferers produce normal levels of SMN protein, but the protein is altered so that it is no longer capable of performing its normal functions within the body. One of the main reasons for this is that these disease-causing alterations in the SMN protein prevent it from localising to the correct places in the body¡¯s cells. By looking at why mutations occur and what they do to divert protein away from the cellular areas where it is required, the Peninsula Medical School team may be able to identify compounds that alter the protein so that it is directed correctly ¨C effectively producing a treatment for the disease.
The research could also have potential bearings on other treatments, such as gene therapy.
The paper highlighting this research is the first to be published by this particular research team, and it has made the front cover of ¡°Human Molecular Genetics¡± ¨C a remarkable achievement for a first time publication.
The research team is developing a number of other research projects in this area, as well as looking at non-invasive ways of carrying out tests in clinical trials ¨C such as identifying SMA from saliva rather than blood samples.
The team is headed up by Dr. Philip Young, researcher and lecturer in biomedical science at the Peninsula Medical School. He said: ¡°Although our results have no initial translational impact on patients, they highlight why alterations in the SMN protein could prevent it from functioning properly. This is important because if we can help the altered protein function we could potentially identify a novel therapeutic approach.¡±
Richard Green, chief executive of The Jennifer Trust for Spinal Muscular Atrophy, added: ¡°Every advance in the scientific understanding of this devastating condition brings us another step closer to an effective treatment. New discoveries lead to new hope for the many thousands of families affected by SMA. We are very pleased to hear this news.¡±
— Article compiled by Dr. Vimmi from medical news release.
- « Lung :: Treat all patients with rare lung disease to prevent stroke, say doctors
- Healthcare :: NSF awards Stevens team $1 million for research on smart, bacteria-repellent nanohydrogels »
Sub-editorMuscular Atrophy :: Molecular medical research points to treatment of spinal muscular atrophy
by Sub-editor ( Author at Spirit India )
Posted on November 4th, 2007 at 8:46 am.
Find more from SpiritIndia on: Health